Joseph Schwartz
Stock Analyst at Leerink Partners
(4.10)
# 535
Out of 5,105 analysts
157
Total ratings
33.82%
Success rate
21.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLT Applied Therapeutics | Downgrades: Market Perform | $2 → $1 | $0.12 | +752.51% | 3 | Dec 3, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $83.40 | +91.85% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $9.43 | +48.46% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $1.05 | +90.48% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $53.31 | +12.55% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $15.85 | +0.95% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $19.51 | +207.53% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $74.61 | +54.15% | 1 | Nov 10, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | $65 → $72 | $71.83 | +0.24% | 4 | Oct 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $80 → $88 | $50.49 | +74.29% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $21.53 | -30.33% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $16.91 | +18.27% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $115 | $197.01 | -41.63% | 4 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $13.00 | -7.69% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $38.86 | -27.95% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $34.83 | +14.84% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.20 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $5.87 | +104.43% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.17 | +268.66% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $1.11 | -9.91% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $75.64 | -36.54% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $24.16 | -25.50% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $80.82 | -57.93% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $220.42 | -26.05% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.60 | +177.78% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $5.66 | +483.04% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $36.23 | +198.10% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $23.62 | +27.01% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $95.35 | -68.54% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $10.55 | +32.70% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.33 | +415.02% | 2 | Sep 26, 2017 |
Applied Therapeutics
Dec 3, 2025
Downgrades: Market Perform
Price Target: $2 → $1
Current: $0.12
Upside: +752.51%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $83.40
Upside: +91.85%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $9.43
Upside: +48.46%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $1.05
Upside: +90.48%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $53.31
Upside: +12.55%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $15.85
Upside: +0.95%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $19.51
Upside: +207.53%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $74.61
Upside: +54.15%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: $65 → $72
Current: $71.83
Upside: +0.24%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $50.49
Upside: +74.29%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $21.53
Upside: -30.33%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $16.91
Upside: +18.27%
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $197.01
Upside: -41.63%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $13.00
Upside: -7.69%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $38.86
Upside: -27.95%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $34.83
Upside: +14.84%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.20
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.87
Upside: +104.43%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.17
Upside: +268.66%
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.11
Upside: -9.91%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $75.64
Upside: -36.54%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $24.16
Upside: -25.50%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $80.82
Upside: -57.93%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $220.42
Upside: -26.05%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.60
Upside: +177.78%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $5.66
Upside: +483.04%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $36.23
Upside: +198.10%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $23.62
Upside: +27.01%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $95.35
Upside: -68.54%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $10.55
Upside: +32.70%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.33
Upside: +415.02%